Aurinia Pharmaceuticals Inc. (AUPH) Stock Analysis & Investment Frameworks
Aurinia Pharmaceuticals Inc. (AUPH) stock analysis on Invetso. Review Aurinia Pharmaceuticals Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Aurinia Pharmaceuticals Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: CA
Aurinia Pharmaceuticals Inc. Key Financial Metrics
- Market Cap: $2.23B
- Revenue: $283.06M
- P/E Ratio: 7.75
- ROE: 59.00%
- ROIC: 21.27%
- Dividend Yield: N/A
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
Aurinia Pharmaceuticals Inc. Investment Frameworks
Invetso analyzes Aurinia Pharmaceuticals Inc. (AUPH) across the following frameworks:
- Aurinia Pharmaceuticals Inc. 10Y Growth Potential
- Aurinia Pharmaceuticals Inc. Scenario Analysis
- Aurinia Pharmaceuticals Inc. Risks & Opportunities
- Aurinia Pharmaceuticals Inc. Economic Moat
- Aurinia Pharmaceuticals Inc. Business Model
- Aurinia Pharmaceuticals Inc. Management
- Aurinia Pharmaceuticals Inc. SWOT Analysis
- Aurinia Pharmaceuticals Inc. Porter's 5 Forces
- Aurinia Pharmaceuticals Inc. PESTLE Analysis
- Aurinia Pharmaceuticals Inc. ESG Analysis